All In Biotech

Drug Trial Radar · NCT07667868

A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma

A Phase I, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Sponsor type
Industry
First posted
Jun 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed/Refractory Multiple Myeloma.

Conditions

  • Relapsed/Refractory Multiple Myeloma (RRMM)

Interventions

  • BP2202Biological

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs; Part A)Time frame: Up to 6 weeks
  2. Incidence of adverse events (AEs; Parts A and B)Time frame: Up to approximately 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.